Literature DB >> 26060030

Anticoagulation management associated with extracorporeal circulation.

Roman M Sniecinski1, Jerrold H Levy2.   

Abstract

The use of extracorporeal circulation requires anticoagulation to maintain blood fluidity throughout the circuit, and to prevent thrombotic complications. Additionally, adequate suppression of hemostatic activation avoids the unnecessary consumption of coagulation factors caused by the contact of blood with foreign surfaces. Cardiopulmonary bypass represents the greatest challenge in this regard, necessitating profound levels of anticoagulation during its conduct, but also quick, efficient reversal of this state once the surgical procedure is completed. Although extracorporeal circulation has been around for more than half a century, many questions remain regarding how to best achieve anticoagulation for it. Although unfractionated heparin is the predominant agent used for cardiopulmonary bypass, the amount required and how best to monitor its effects are still unresolved. This review discusses the use of heparin, novel anticoagulants, and the monitoring of anticoagulation during the conduct of cardiopulmonary bypass.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  antithrombin III; cardiopulmonary bypass; heparin resistance; unfractionated heparin; whole-blood-activated coagulation time

Mesh:

Substances:

Year:  2015        PMID: 26060030     DOI: 10.1016/j.bpa.2015.03.005

Source DB:  PubMed          Journal:  Best Pract Res Clin Anaesthesiol        ISSN: 1521-6896


  6 in total

1.  Combining Heparin and a FX/Xa Aptamer to Reduce Thrombin Generation in Cardiopulmonary Bypass and COVID-19.

Authors:  Charlene V Chabata; James W Frederiksen; Lyra B Olson; Ibtehaj A Naqvi; Sharon E Hall; Ruwan Gunaratne; Bryan D Kraft; Loretta G Que; Lingye Chen; Bruce A Sullenger
Journal:  Nucleic Acid Ther       Date:  2022-01-12       Impact factor: 4.244

2.  Anticoagulation management during cardiopulmonary bypass in patients with antiphospholipid syndrome.

Authors:  Tatsuya Seki; Yasushige Shingu; Hiroshi Sugiki; Satoru Wakasa; Hiroki Katoh; Tomonori Ooka; Tsuyoshi Tachibana; Suguru Kubota; Yoshiro Matsui
Journal:  J Artif Organs       Date:  2018-03-14       Impact factor: 1.731

3.  Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass.

Authors:  Ruwan Gunaratne; Shekhar Kumar; James W Frederiksen; Steven Stayrook; Jens L Lohrmann; Kay Perry; Kristin M Bompiani; Charlene V Chabata; Nabil K Thalji; Michelle D Ho; Gowthami Arepally; Rodney M Camire; Sriram Krishnaswamy; Bruce A Sullenger
Journal:  Nat Biotechnol       Date:  2018-06-04       Impact factor: 54.908

Review 4.  The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology.

Authors:  Jonathan E Millar; Jonathon P Fanning; Charles I McDonald; Daniel F McAuley; John F Fraser
Journal:  Crit Care       Date:  2016-11-28       Impact factor: 9.097

5.  miR-3064-5p and miR-4745-5p affect heparin sensitivity in patients undergoing cardiac surgery by regulating AT-III and factor X mRNA levels.

Authors:  Hai-Ping Ma; Min Fu; Maisitanguli Masula; Chang-Shuang Xing; Qiang Zhou; Jing-Tong Tan; Jiang Wang
Journal:  Front Physiol       Date:  2022-08-12       Impact factor: 4.755

6.  Can We Rely on the Activated Clotting Time to Measure Heparin Anticoagulation? A Clinical Evaluation of Two ACT Monitors.

Authors:  Samuel Nilsson; Micael Appelblad; Staffan Svenmarker
Journal:  J Extra Corpor Technol       Date:  2020-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.